Brokerages Set Heron Therapeutics, Inc. (NASDAQ:HRTX) PT at $4.50

Heron Therapeutics, Inc. (NASDAQ:HRTX) has earned a consensus rating of “Hold” from the five ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $4.50.

Several equities research analysts have commented on HRTX shares. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Heron Therapeutics in a research report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, November 4th.

Heron Therapeutics Stock Performance

HRTX stock opened at $1.15 on Thursday. The company has a 50-day simple moving average of $1.33 and a 200 day simple moving average of $1.29. The company has a quick ratio of 1.78, a current ratio of 2.56 and a debt-to-equity ratio of 19.89. The company has a market capitalization of $210.86 million, a P/E ratio of -12.78 and a beta of 1.25. Heron Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $2.68.

Hedge Funds Weigh In On Heron Therapeutics

Several hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC raised its stake in shares of Heron Therapeutics by 215.2% in the 4th quarter. Squarepoint Ops LLC now owns 677,947 shares of the biotechnology company’s stock valued at $881,000 after acquiring an additional 462,840 shares in the last quarter. Panagora Asset Management Inc. acquired a new stake in Heron Therapeutics during the fourth quarter worth about $572,000. Barclays PLC increased its stake in Heron Therapeutics by 8.5% during the fourth quarter. Barclays PLC now owns 303,209 shares of the biotechnology company’s stock valued at $394,000 after acquiring an additional 23,852 shares during the period. Rubric Capital Management LP raised its holdings in Heron Therapeutics by 3.3% in the 4th quarter. Rubric Capital Management LP now owns 30,046,828 shares of the biotechnology company’s stock valued at $39,061,000 after acquiring an additional 946,100 shares in the last quarter. Finally, Headlands Technologies LLC grew its holdings in shares of Heron Therapeutics by 158.3% during the 4th quarter. Headlands Technologies LLC now owns 51,287 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 31,431 shares in the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.